
Join to view full profile
20 Duke Medicine CircleDurham, NC 27710
Phone+1 919-684-8964
Fax+1 919-684-5325
Dr. McKinney is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
Duke University HospitalResidency, Internal Medicine, 2006 - 2009
Duke University School of MedicineClass of 2006
Certifications & Licensure
NC State Medical License 2006 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Publications & Presentations
PubMed
- Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.Adam J Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Herbert Eradat
Blood Neoplasia. 2026-08-01 - Infectious Complications of CD19-targeted Chimeric Antigen Receptor T-cell Therapy: a Multicenter Cohort Study.Jonathan Huggins, Julia A Messina, Jennifer Saullo, Jiayi Xie, Amy Zhang
Open Forum Infectious Diseases. 2026-07-01 - 1 citationsSafety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2...M Lia Palomba, Manish R Patel, Toby A Eyre, Wojciech Jurczak, David Lewis
The Lancet. Haematology. 2026-05-01
Abstracts/Posters
- A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell LymphomaMatthew S. McKinney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular LymphomaMatthew S. McKinney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Reflections on Early Challenges and Experiences in Treating DLBCLJanuary 27th, 2025
Hepatosplenic T-cell Lymphoma: Recent Progress and Future ConsiderationsSeptember 16th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: